Sanofi India Limited has informed the Exchange regarding a press release dated July 16, 2025, titled "Sanofi India Limited and Emcure announce exclusive distribution partnership to broaden reach of Sanofi s Oral Anti-diabetic drugs".
SANOFI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sanofi India's Board approved three matters on July 16, 2025. First, Rachid Ayari was appointed as Interim Managing Director for 6 months (July 21, 2025 to January 20, 2026) in addition to his current role as CFO, following the departure of the previous MD. Second, Aniket Raje was appointed as Head of Regulatory Affairs effective August 1, 2025, bringing over 21 years of pharma industry experience. Third, and most significant, the Board approved an exclusive 5-year distribution and promotion agreement with Emcure Pharmaceuticals for Sanofi's oral anti-diabetic (OAD) portfolio, including the well-known brands Amaryl® and Cetapin®. Sanofi will retain ownership and continue manufacturing these brands at its plants in India and abroad, while Emcure will use its deep distribution network to promote and sell them across India. No employees will transition from Sanofi to Emcure under this arrangement.
The Emcure partnership lets Sanofi tap into a broader distribution network for its established diabetes brands in a market with over 100 million type 2 diabetes patients, potentially boosting revenue without changing the manufacturing or ownership structure. For shareholders, the interim MD arrangement keeps leadership continuity during the search for a permanent chief, while the focus on growing a key therapeutic segment is a positive strategic move.